基于专利数据的血管内支架研究发展趋势分析
|
摘要
目的血管内支架植入是临床上治疗狭窄类心血管疾病的重要手段。本文对血管内支架相关专利进行检索和后续分析,为我国的血管内支架技术的发展提供参考。方法使用世界知识产权组织以及中国国家知识产权局数据库,通过设定stent、intravascular、metal、bare metal、coating、drug-eluting、bioabsorbable、biodegradable等为关键词,将检索结果按照不同时间、不同申请人及IPC分类号进行归纳总结。结果当今世界,以美国为首的发达国家依然为血管内支架技术的领头羊,特别是美国,技术远远领先于世界其他国家;我国技术就国内市场而言已经完全打破国外巨头的技术垄断;在我国专利申请数量中,排在第一位的申请地区为上海,在国外来华专利申请中,美国数量最多;另外,从分析结果可以发现,未来冠脉支架技术将会以可降解支架为主。结论全球的血管内支架处于稳步发展阶段。我国的血管支架技术和产品已占领国内市场的绝大部分,完全打破国外巨头的垄断,发展前景可观。
Objective Intravascular stent implantation is an important method for the treatment of cardiovascular diseases. This paper provides the references for the development of China's stent technology based on the retrieval and subsequent analyses of stent related patents. Methods We analyze the patents of the intravascular stents based on the WIPO patent scope and SIPO. We set stent,intravascular,metal,bare metal,coating,drug-eluting,bioabsorbable,biodegradable etc. as key words and then summarize the results according to different time,different applicants and different IPC classification numbers. Results Nowadays,the developed countries headed by the United States are still the leaders in this technology,and especially,the United States is far ahead of other countries in the world. In our country,the technology has broken the monopoly of foreign technology giants in the domestic market. Shanghai ranked first in the application area in China. The United States is the largest in the number of patent applications abroad in China. Inthe future,biodegradable stents will become the mainstream trend on coronary stent. Conclusion Global endovascular stent is in a steady development stage. Stent technology and products from China have occupied the domestic market,completely breaking the foreign giants' monopoly.
Objective Intravascular stent implantation is an important method for the treatment of cardiovascular diseases. This paper provides the references for the development of China's stent technology based on the retrieval and subsequent analyses of stent related patents. Methods We analyze the patents of the intravascular stents based on the WIPO patent scope and SIPO. We set stent,intravascular,metal,bare metal,coating,drug-eluting,bioabsorbable,biodegradable etc. as key words and then summarize the results according to different time,different applicants and different IPC classification numbers. Results Nowadays,the developed countries headed by the United States are still the leaders in this technology,and especially,the United States is far ahead of other countries in the world. In our country,the technology has broken the monopoly of foreign technology giants in the domestic market. Shanghai ranked first in the application area in China. The United States is the largest in the number of patent applications abroad in China. Inthe future,biodegradable stents will become the mainstream trend on coronary stent. Conclusion Global endovascular stent is in a steady development stage. Stent technology and products from China have occupied the domestic market,completely breaking the foreign giants' monopoly.
引文
[1]温绍君,张蓓.高血压的正确诊断及恰当治疗[J].中国老年心脑血管疾病杂志,2014,16(4):337-339.
[2]Dearani JA,Jacobs JP,Bolman RM,et al.Humanitarian outreach in cardiothoracic surgery:from setup to sustainability[J].Annals of Thoracic Surgery,2016,102(3):1004-1011.
[3]孙大明.血管内支架涂层超声雾化喷涂装置设计及涂层制备工艺优化[D].重庆:重庆大学,2013.
[4]中华医学会心血管病学分会预防学组,中国康复医学会心血管病专业委员会.冠心病患者运动治疗中国专家共识[J].中华心血管病杂志,2015,43(7):575-588.
[5]詹洪春,刘志学.“医心者”葛均波的“两会视野”[J].中国医药导报,2016,13(10):1-3.
[6]Wu X,Zhao Y,Tang C,et al.Re-endothelialization study on endovascular stents seeded by endothelial cells through up-or downregulation of VEGF[J].ACS Applied Materials&Interfaces,2016,8(11):7578-7589.
[7]奚廷斐,郑玉峰.介入医学工程现状和发展趋势[J].中国材料进展,2010(12):17-26.Xi Tingfei,Zheng Yufeng.Current situation and development tendency of interventional medical device[J].Materials China,2010(12):17-26.
[8]刘道志,奚廷斐.微创介入医疗器械与材料产业的现状和发展趋势[J].中国医疗器械信息,2006(12):1-14,1.Liu Daozhi,Xi Tingfei.Current situation and development tendency of interventional medical device&material industry[J].China Medical Device Information,2006(12):1-14,1.
[9]Garg S,Serruys PW.Coronary stents current status[J].Journal of the American College of Cardiology,2010,56(10):S1-S42.
[10]沈莹冉,周永新.生物可降解冠状动脉支架的研究进展[J].外科研究与新技术,2014,3(4):267-274.Shen Yingran,Zhou Yongxin.Process of biodegradable coronary stents[J].Surgical Research and New Technique,2014,3(4):267-274.
[11]Bundhun PK,Bhurtu A,Soogund MZS,et al.Comparing the clinical outcomes between drug eluting stents and bare metal stents in patients with insulin-treated type 2 diabetes mellitus:a systematic review and meta-analysis of 10 randomized controlled trials[J].Plos One,2016,11(4):e0154064.
[12]迟新栋,玛依努尔·斯买拉洪,甘庆雷,等.可降解涂层雷帕霉素洗脱支架在冠状动脉狭窄病变处理中的安全性[J].中国组织工程研究,2015,19(34):5501-5505.Chi Xindong,Mayinuer Simailahong,Gan Qinglei,Yang Na,et al.Biodegradable sirolimus eluting stents in coronary artery stenosis:a safety evaluation[J].Chinese Journal of Tissue Engineering Research,2015,19(34):5501-5505.
[13]Sun D,Zheng Y,Yin T,et al.Coronary drug-eluting stents:From design optimization to newer strategies:Coronary Drug-Eluting Stents[J].Journal of Biomedical Materials Research Part A,2014,102(5):1625-1640.
[14]张茵.生物及金属可降解支架在冠状动脉粥样硬化性心脏病介入治疗中的研究进展[J].心血管病学进展,2013,34(1):38-41.Zhang Yin.Biodegradable and bioabsorbable stents in percutaneous coronary intervention[J].Advances in Cardiovascular Diseases,2013,34(1):38-41.
[15]Kukreja N,Onuma Y,Daemen J,et al.The future of drug-eluting stents[J].Pharmacological Research,2008,57(3):171-180.
[16]Lindholm D,James S.Bioresorbable stents in PCI[J].Current Cardiology Reports,2016,18(8):74.
[17]颜涛,王金晶,崔文昊.血管支架专利现状分析[J].统计与分析,2015(10):56-61.Yan Tao,Wang Jinjing,Cui Wenhao.Analysis of patent status of vascular stents[J].Statistics&Analysis,2015(10):56-61.
[18]赵亚娟,董瑜,朱相丽.专利分析及其在情报研究中的应用[J].图书情报工作,2006(5):19-22.Zhao Yajuan,Dong Yu,Zhu Xiangli.Patent analysis and its application in information research[J].Library and information service,2006(5):19-22.
[19]唐炜,刘细文.专利分析法及其在企业竞争对手分析中的应用[J].现代情报,2005,25(9):179-183,186.Tang Wei,Liu Xiwen.Patent analysis and its application in the analysis of competitors[J].Modern Information,2005,25(9):179-183,186.
[20]左晶.IPC和USC分类体系下专利检索的对比分析[J].现代情报,2007,27(1):130-132.Zuo Jing.Comparative analysis of patent retrieval under IPC and USC classification system[J].Modern Information,2007,27(1):130-132.
[21]韩红旗,付媛,朱礼军.基于专利IPC分类号的技术竞争对象的群组分析方法[J].情报工程,2015(4):77-87.Han Hongqi,Fu Yuan,Zhu Lijun.Patent technology competitor group analysis method based on IPC[J].Technology Intelligence Engineering,2015(4):77-87.
[22]田虹,孙冲,胡元,等.“专利地图制作与分析”开放实验的实践[J].实验室研究与探索,2015(3):216-219,258.Tian Hong,Sun Chong,Hu Yuan,et al.Practice of Opening Experiment Related to Making and Analyzing the Patent Maps of Biomaterials[J].Research and Exploration in Laboratory,2015(3):216-219,258.
[23]Ma J,Zhao N,Betts L,et al.Bio-adaption between magnesium alloy stent and the blood vessel:a review[J].Journal of Materials Science&Technology,2016,32(9):815-826.
[24]Cllet C,de Winter RJ,Onuma Y,et al.The absorb bioresorbable vascular scaffold for the treatment of coronary artery disease[J].Expert Opinion on Drug Delivery,2016,13(10):1489-1499.
[25]Haude M,Erbel R,Erne P,et al.Safety and performance of the drug-eluting absorbable metal scaffold(DREAMS)in patients with de-novo coronary lesions:12 month results of the prospective,multicentre,first-in-man BIOSOLVE-I trial[J].Lancet,2013,381(9869):836-844.
[26]Lim GB.Interventional cardiology:DREAMS of a bioabsorbable stent coming true[J].Nature Reviews Cardiology,2013,10(3):120.
[27]Chakraborty R,Patra S,Banerjee S,et al.Outcome of everolimus eluting bioabsorbable vascular scaffold(BVS)compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction(STEMI)—a comparative study[J].Cardiovascular Revascularization Medicine,2016,17(3):151-154.
[28]张曌彤,李若松,胡亚娟等.浅谈国产血管支架的发展历程[J].中国医疗设备,2016,31(6):178-181.Zhang Zhaotong,Li Ruosong,Hu Yajuan,et al.Discussion on the development of domestic vascular stents[J].China Medical Devices,2016,31(6):178-181.
[29]Kilkis S.Sustainability-oriented innovation system analyses of Brazil,Russia,India,China,South Africa,Turkey and Singapore[J].Journal of Cleaner Production,2016,130:235-247.
[2]Dearani JA,Jacobs JP,Bolman RM,et al.Humanitarian outreach in cardiothoracic surgery:from setup to sustainability[J].Annals of Thoracic Surgery,2016,102(3):1004-1011.
[3]孙大明.血管内支架涂层超声雾化喷涂装置设计及涂层制备工艺优化[D].重庆:重庆大学,2013.
[4]中华医学会心血管病学分会预防学组,中国康复医学会心血管病专业委员会.冠心病患者运动治疗中国专家共识[J].中华心血管病杂志,2015,43(7):575-588.
[5]詹洪春,刘志学.“医心者”葛均波的“两会视野”[J].中国医药导报,2016,13(10):1-3.
[6]Wu X,Zhao Y,Tang C,et al.Re-endothelialization study on endovascular stents seeded by endothelial cells through up-or downregulation of VEGF[J].ACS Applied Materials&Interfaces,2016,8(11):7578-7589.
[7]奚廷斐,郑玉峰.介入医学工程现状和发展趋势[J].中国材料进展,2010(12):17-26.Xi Tingfei,Zheng Yufeng.Current situation and development tendency of interventional medical device[J].Materials China,2010(12):17-26.
[8]刘道志,奚廷斐.微创介入医疗器械与材料产业的现状和发展趋势[J].中国医疗器械信息,2006(12):1-14,1.Liu Daozhi,Xi Tingfei.Current situation and development tendency of interventional medical device&material industry[J].China Medical Device Information,2006(12):1-14,1.
[9]Garg S,Serruys PW.Coronary stents current status[J].Journal of the American College of Cardiology,2010,56(10):S1-S42.
[10]沈莹冉,周永新.生物可降解冠状动脉支架的研究进展[J].外科研究与新技术,2014,3(4):267-274.Shen Yingran,Zhou Yongxin.Process of biodegradable coronary stents[J].Surgical Research and New Technique,2014,3(4):267-274.
[11]Bundhun PK,Bhurtu A,Soogund MZS,et al.Comparing the clinical outcomes between drug eluting stents and bare metal stents in patients with insulin-treated type 2 diabetes mellitus:a systematic review and meta-analysis of 10 randomized controlled trials[J].Plos One,2016,11(4):e0154064.
[12]迟新栋,玛依努尔·斯买拉洪,甘庆雷,等.可降解涂层雷帕霉素洗脱支架在冠状动脉狭窄病变处理中的安全性[J].中国组织工程研究,2015,19(34):5501-5505.Chi Xindong,Mayinuer Simailahong,Gan Qinglei,Yang Na,et al.Biodegradable sirolimus eluting stents in coronary artery stenosis:a safety evaluation[J].Chinese Journal of Tissue Engineering Research,2015,19(34):5501-5505.
[13]Sun D,Zheng Y,Yin T,et al.Coronary drug-eluting stents:From design optimization to newer strategies:Coronary Drug-Eluting Stents[J].Journal of Biomedical Materials Research Part A,2014,102(5):1625-1640.
[14]张茵.生物及金属可降解支架在冠状动脉粥样硬化性心脏病介入治疗中的研究进展[J].心血管病学进展,2013,34(1):38-41.Zhang Yin.Biodegradable and bioabsorbable stents in percutaneous coronary intervention[J].Advances in Cardiovascular Diseases,2013,34(1):38-41.
[15]Kukreja N,Onuma Y,Daemen J,et al.The future of drug-eluting stents[J].Pharmacological Research,2008,57(3):171-180.
[16]Lindholm D,James S.Bioresorbable stents in PCI[J].Current Cardiology Reports,2016,18(8):74.
[17]颜涛,王金晶,崔文昊.血管支架专利现状分析[J].统计与分析,2015(10):56-61.Yan Tao,Wang Jinjing,Cui Wenhao.Analysis of patent status of vascular stents[J].Statistics&Analysis,2015(10):56-61.
[18]赵亚娟,董瑜,朱相丽.专利分析及其在情报研究中的应用[J].图书情报工作,2006(5):19-22.Zhao Yajuan,Dong Yu,Zhu Xiangli.Patent analysis and its application in information research[J].Library and information service,2006(5):19-22.
[19]唐炜,刘细文.专利分析法及其在企业竞争对手分析中的应用[J].现代情报,2005,25(9):179-183,186.Tang Wei,Liu Xiwen.Patent analysis and its application in the analysis of competitors[J].Modern Information,2005,25(9):179-183,186.
[20]左晶.IPC和USC分类体系下专利检索的对比分析[J].现代情报,2007,27(1):130-132.Zuo Jing.Comparative analysis of patent retrieval under IPC and USC classification system[J].Modern Information,2007,27(1):130-132.
[21]韩红旗,付媛,朱礼军.基于专利IPC分类号的技术竞争对象的群组分析方法[J].情报工程,2015(4):77-87.Han Hongqi,Fu Yuan,Zhu Lijun.Patent technology competitor group analysis method based on IPC[J].Technology Intelligence Engineering,2015(4):77-87.
[22]田虹,孙冲,胡元,等.“专利地图制作与分析”开放实验的实践[J].实验室研究与探索,2015(3):216-219,258.Tian Hong,Sun Chong,Hu Yuan,et al.Practice of Opening Experiment Related to Making and Analyzing the Patent Maps of Biomaterials[J].Research and Exploration in Laboratory,2015(3):216-219,258.
[23]Ma J,Zhao N,Betts L,et al.Bio-adaption between magnesium alloy stent and the blood vessel:a review[J].Journal of Materials Science&Technology,2016,32(9):815-826.
[24]Cllet C,de Winter RJ,Onuma Y,et al.The absorb bioresorbable vascular scaffold for the treatment of coronary artery disease[J].Expert Opinion on Drug Delivery,2016,13(10):1489-1499.
[25]Haude M,Erbel R,Erne P,et al.Safety and performance of the drug-eluting absorbable metal scaffold(DREAMS)in patients with de-novo coronary lesions:12 month results of the prospective,multicentre,first-in-man BIOSOLVE-I trial[J].Lancet,2013,381(9869):836-844.
[26]Lim GB.Interventional cardiology:DREAMS of a bioabsorbable stent coming true[J].Nature Reviews Cardiology,2013,10(3):120.
[27]Chakraborty R,Patra S,Banerjee S,et al.Outcome of everolimus eluting bioabsorbable vascular scaffold(BVS)compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction(STEMI)—a comparative study[J].Cardiovascular Revascularization Medicine,2016,17(3):151-154.
[28]张曌彤,李若松,胡亚娟等.浅谈国产血管支架的发展历程[J].中国医疗设备,2016,31(6):178-181.Zhang Zhaotong,Li Ruosong,Hu Yajuan,et al.Discussion on the development of domestic vascular stents[J].China Medical Devices,2016,31(6):178-181.
[29]Kilkis S.Sustainability-oriented innovation system analyses of Brazil,Russia,India,China,South Africa,Turkey and Singapore[J].Journal of Cleaner Production,2016,130:235-247.